Credit Suisse

ANZ New Zealand this week became the latest in a slew of Antipodean financial institutions to print Swiss franc denominated debt.

Central American Bank for Economic Integration (Cabei) became the first non-European SSA to tap the Swiss market this year on Tuesday.

Attractive spreads have improved sentiment considerably in the covered bond market, but senior issuance remains elusive as cautious banks deal with gloomy data.

It’s been an axiom of recent bank restructurings that more private banking and wealth management is better. Gather the substantial and sticky deposits of the wealthy, harness their investments, and skim fees off the top, using as little balance sheet as possible. Dodge the tax evasion fines, and it’s a good and stable business to be in.

Alliance Automotive, the Blackstone-owned French car parts supplier, this week tapped its 2021 notes for €70m as the European high yield market tries to regain momentum after a poor January.

SolarWinds, the US IT management software firm, priced its $1.5bn first lien acquisition debt package at a hefty discount on Monday while finalising the euro tranche size.

Indonesian telecom giant XL Axiata is preparing a rights issue as it looks to pay back a $500m shareholder loan.

Swiss franc investors made the most of a rare opportunity to buy Austrian sub-sovereign paper on Thursday when Land Niederoesterreich (Lower Austria) tapped its April 2021 and September 2023 bonds.

One of Credit Suisse's most senior leveraged finance bankers is heading back to Switzerland to join the management team of the group's Swiss entity, as it prepares for a partial IPO in the next two years.

Postal Savings Bank of China has selected five banks to lead its jumbo $15bn IPO, which is set to become the largest listing in Hong Kong in five years.

Infinitas, the educational publisher, has set final terms on the €435m senior secured debt package backing its acquisition by Compass Partners from Bridgepoint.

Samsung Bioepis, the pharmaceutical arm of the South Korean conglomerate, has decided to postpone its Nasdaq IPO due to valuation issues and to make way for the listing of Samsung BioLogics.